Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering
multiple myeloma with high risk of progression to active multiple myeloma. BHQ880 will be
administered every 28 days in previously untreated patients. Disease assessments will be
performed monthly and effects on bone metabolism will be assessed by measurement of serum and
urine bone biomarkers, changes in BMD , and QCT with FEA. Additionally, the PK profile of
BHQ880 as a single agent and following multiple doses will be obtained.